Senolytics Evidence Grades
A physician review of the senolytic and senomorphic landscape — dasatinib + quercetin, fisetin, navitoclax, venetoclax, piperlongumine, and the senomorphics — graded by one thing: the stage of completed human evidence for each as a senescence-targeting intervention.
Built and medically reviewed by Charles Kamen, MD, board-certified neurologist ·
Senolytics are among the most hyped frontiers in longevity medicine — and among the least proven in humans. Cellular senescence is a genuine hallmark of aging (see our hallmarks map), so the idea of clearing senescent “zombie” cells is scientifically sound and actively researched. But of the major candidates, only the dasatinib + quercetin combination has completed small human clinical data (Hickson 2019), and no senolytic is FDA-approved for aging. The most potent preclinical senolytic, navitoclax, is limited by toxicity in humans. This page maps the landscape honestly; it does not prescribe it.
Why this is a hub, not a duplicate: the per-molecule longevity tiers for dasatinib + quercetin and fisetin already live on our longevity drug evidence index. This page does something different — it explains the science of senescence and senolytic vs senomorphic mechanisms, and maps where each compound stands in human evidence as a senescence intervention specifically. It pairs with our hallmarks map (where senescence sits in aging biology) and the biological-age tests page (how senescence burden is measured).
The stages here mirror the honesty of our drug A–D rubric: Tier A (FDA-approved senolytic for aging, multi-RCT) is unmet — no compound qualifies. Tier C is where the leading senolytics sit (completed small human trials), and Tier D is the bulk of the pipeline (preclinical or no completed human senescence-outcome data). Of the 8 compounds mapped, 5 have any completed human data as a senescence intervention at all.
Senolytics vs senomorphics: the key distinction
Senolytics kill senescent cells. Dasatinib + quercetin, fisetin, navitoclax, venetoclax, piperlongumine. Intermittent dosing exploits the cell’s vulnerability window.
Senomorphics calm senescent cells. They suppress the SASP or the senescent state without killing the cell — rapamycin and metformin are examples. Require continuous dosing.
Senescence is a real hallmark of aging. Named in López-Otín 2013 and retained in the 2023 expansion. The biology is sound; the human interventions are early.
No senolytic is FDA-approved for aging. Several compounds are FDA-approved for cancer (dasatinib, venetoclax) — that is not senolytic or longevity evidence.
Potent in mice ≠ safe in humans. Navitoclax is among the strongest preclinical senolytics but causes platelet loss in people — a classic translational wall.
The strongest human lever is lifestyle. Exercise and healthy body composition are associated with lower senescent-cell burden — ahead of any senolytic today.
The human-evidence stages
Each compound is graded by the stage of completed human evidence for it specifically as a senescence-targetingintervention — not its original FDA-approved use.
FDA-approved specifically for clearing senescent cells or treating aging, with multiple completed Phase 3 trials. No compound meets this bar — there is no FDA-approved senolytic.
One or more completed randomized trials on a clinical (not just biomarker) senescence-related endpoint in humans. No major senolytic currently reaches this tier.
A completed small human clinical trial exists — often Phase 1/2, often biomarker-led (e.g., senescent-cell burden in tissue), not yet a clinical outcome. This is where the leading senolytics sit.
Evidence is animal or laboratory, or human data is limited to pharmacokinetics/safety with no senescence-outcome trial. The bulk of the senolytic pipeline today.
Scope note: these stages grade evidence as a senescence intervention specifically. A cancer approval (dasatinib, venetoclax) is not senolytic or longevity evidence. A registered-but-not-finished trial is not completed evidence. For the molecule’s broader longevity tier (which weighs all aging-relevant human data, not only senescence), see our longevity drug evidence index.
The senolytic & senomorphic landscape
| Compound | Class | Stage | Mechanism | Completed human evidence | Note |
|---|---|---|---|---|---|
| Dasatinib + Quercetin (D+Q) | Senolytic | C | Targets the senescent-cell anti-apoptotic (SCAP) network — dasatinib (a kinase inhibitor) disables survival signaling; quercetin (a flavonoid) lowers adjacent resistance. Intermittent dosing exploits senescent cells’ vulnerability windows. | 1 completed small human clinical trial (Hickson 2019): reduced senescent-cell burden in adipose/kidney tissue of adults with diabetic kidney disease. | The senolytic combination with the most completed human data, but that data is small and early. Dasatinib is FDA-approved for oncology — that approval is not senolytic or longevity evidence. Per-molecule grade: Tier C on our drug index. |
| Fisetin | Senolytic | C | A flavonoid (found in strawberries/apples) that selectively induces death in senescent cells; also senomorphic at lower exposure. | Strong preclinical lifespan/healthspan data (Yousefzadeh 2018); completed human data so far is pharmacokinetic/safety, with senolytic-outcome trials (e.g., MAYFLOWER, AFFIRM-LITE) still running. | A widely sold supplement whose human use is ahead of completed outcome evidence. Near the C/D boundary. Per-molecule grade: Tier C on our drug index. |
| Navitoclax (ABT-263) | Senolytic | D | A BCL-2 / BCL-xL inhibitor that removes the anti-apoptotic shield keeping senescent cells alive; among the most potent preclinical senolytics. | Potent in animal models; in humans it is an investigational oncology agent with a well-known limiting toxicity — thrombocytopenia (platelet loss). No completed senescence-outcome trial for aging. | The textbook example of why preclinical senolytic potency does not translate to safe human longevity use. Tier D for aging. Not a consumer supplement. |
| Venetoclax (ABT-199) | Senolytic | D | A BCL-2-selective inhibitor (avoids the BCL-xL-driven platelet toxicity of navitoclax); FDA-approved for certain blood cancers. | FDA-approved in oncology; senescence-clearing use is preclinical/early-stage. No completed senescence-outcome trial for aging. | A safer BCL-2 target than navitoclax, but its senolytic application for aging remains experimental. Tier D for aging; oncology approval is not longevity evidence. |
| Piperlongumine | Senolytic | D | A natural product (from long pepper) that selectively kills senescent cells via oxidative-stress vulnerability. | Preclinical senolytic activity only; no completed human senescence-outcome data. | An active research compound, not a validated intervention. Tier D for aging. |
| Quercetin (alone) | Senomorphic | C | A flavonoid with anti-inflammatory (SASP-suppressing) activity; only weakly senolytic by itself. | Small human trials exist for various endpoints, but as a solo senolytic its effect is modest; the completed human data sits with the D+Q combination rather than quercetin alone. | Often marketed as a standalone senolytic; the stronger signal is as dasatinib’s partner. Senomorphic at typical exposure. |
| Rapamycin / mTOR inhibitors (senomorphic) | Senomorphic | C | mTOR inhibition suppresses the senescence-associated secretory phenotype (SASP) — it quiets senescent cells rather than killing them. | Senomorphic action is part of rapamycin’s broader longevity biology; its strongest completed human data is on immune endpoints (Tier B on our drug index), not specifically on senescence clearance. | A senescent-cell “calmer,” not a “killer.” Graded Tier B for longevity-relevant human evidence on our drug index; included here for the senomorphic contrast. |
| Metformin (senomorphic) | Senomorphic | C | AMPK activation and proposed SASP attenuation; an indirect senescent-cell modulator. | Senomorphic effect is one of several hypothesized anti-aging mechanisms; the human evidence for aging itself is observational (Tier C on our drug index). | A senomorphic adjunct candidate, not a senolytic. Per-molecule grade: Tier C on our drug index. |
How to read this map:the headline is the emptiness at the top — no Tier A or B senolytic exists. The 5 senolytic compounds cluster at Tier C (D+Q, fisetin) and Tier D (navitoclax, venetoclax, piperlongumine). The completed human data that exists is small and often biomarker-led (senescent-cell burden in tissue), not a clinical outcome like lifespan or healthspan. Translational walls are real: navitoclax’s platelet toxicity is the classic reason a powerful mouse senolytic is not a human longevity drug.
Scope & compliance: this page maps the state of senescence research for education, not medical advice. It contains no doses, no protocols, no titration schedules, and no patient outcomes. Several compounds are not FDA-approved, and several FDA-approved drugs (dasatinib, venetoclax) are used off-label in research. No senolytic is approved for aging. Decisions about any medication or supplement should be made with a licensed physician who can evaluate your individual situation.
The science: why senescent cells matter
Senescent cells are cells that have stopped dividing but refuse to die. They accumulate with age and after injury, and instead of quietly sitting still they pump out a cocktail of inflammatory, tissue-remodeling signals called the senescence-associated secretory phenotype (SASP). The SASP is what makes senescent cells harmful: it spreads inflammation, corrupts neighboring cells, and is implicated in many age-related diseases. This is why cellular senescence is an established hallmark of aging (López-Otín 2013, retained in the 2023 expansion).
That biology is why senolytics generate so much excitement. If senescent cells drive aging-related damage, then clearing them could, in principle, improve healthspan. The principle is sound; the problem is the execution in humans: selectively killing one cell type without harming the rest of the body is hard, the cells exist in many tissues, and the most potent candidates (BCL-xL inhibitors) hit cells we need (platelets). Progress is real but measured in small clinical trials and running outcome studies, not in approved therapies.
How a physician frames senolytics today
A thoughtful physician tracks senolytics as a promising research frontier, not a default therapy. The honest framing for a patient today: cellular senescence is real, senolytics are scientifically interesting, the completed human evidence is small and early, and the highest-evidence lever against senescent-cell burden is the same unglamorous foundation that helps every other hallmark — exercise, healthy body composition, adequate sleep, and metabolic health. Those are associated with lower senescent-cell burden and act across multiple hallmarks at once.
If and when an experimental senolytic enters the conversation, it is with eyes open about the tier, the toxicity profile (especially for any drug like dasatinib or a BCL-2 inhibitor), and the fact that no senolytic is approved for aging. We do not sell senolytic “stacks.” Care starts with an $88 evaluation built around your labs, history, and goals. For the full service overview, see physician-led longevity medicine.
Senolytics in Las Vegas
The research does not change by ZIP code — but the sales pressure does. Las Vegas has a dense market of concierge and med-spa longevity programs that sell fisetin and senolytic “protocols” as established anti-aging regimens, often presenting Tier C/D compounds as if they were proven therapies. The honest read is the opposite: this is a frontier with one small completed human trial and a pipeline still mostly in preclinical or early-phase work.
Whether you visit our southeast Las Vegas clinic at Eastern Avenue and the 215 from Henderson, Summerlin, or Green Valley — or meet Dr. Kamen by secure telehealth anywhere in Nevada — the conversation is the same: where each compound actually sits in the human evidence, what the real risk profile is, and what an evidence-based plan looks like for your goals. Visit our Las Vegas clinic to start.
Selected Research
- Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin. EBioMedicine. 2019;47:446-456.
- Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28.
- Zhang L, et al. Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest. 2022;132(15).
- Wissler Gerdes EO, et al. Discovery, development, and future application of senolytics: theories and predictions. FEBS J. 2020;287(12):2418-2427.
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278.
Anchors for the senolytic/senomorphic landscape only — the completed D+Q human trial, fisetin preclinical lifespan, senescence reviews, and the hallmark framework. Mechanistic and human-stage context, not a treatment claim. Nothing here is medical advice.
Senolytics FAQ
What are senolytics?
Senolytics are a class of compounds designed to selectively clear senescent cells — the damaged, non-dividing “zombie” cells that accumulate with age and secrete inflammatory signals that harm nearby tissue (the senescence-associated secretory phenotype, or SASP). Cellular senescence is one of the established hallmarks of aging, so clearing these cells is one of the most actively researched strategies in longevity medicine. As of 2026, senolytics remain largely experimental in humans: only the dasatinib + quercetin combination has completed small human clinical data, and no senolytic is FDA-approved for aging.
What is the difference between senolytics and senomorphics?
They act on senescent cells in opposite ways. Senolytics kill senescent cells outright — dasatinib + quercetin, fisetin, and the BCL-2/BCL-xL inhibitors (navitoclax, venetoclax) fall here. Senomorphics (also called senostatics) do not kill the cell; they suppress the harmful secretions (SASP) or the senescent state itself — rapamycin and metformin are examples. The distinction matters because senolytics create a clearing event (intermittent dosing), while senomorphics require continuous suppression. Both remain experimental for aging in humans.
Do senolytics have human evidence?
Some, but it is early and small. The dasatinib + quercetin combination has a completed small human clinical trial showing it reduced senescent-cell burden in the adipose and kidney tissue of adults with diabetic kidney disease (Hickson 2019) — real but preliminary. Fisetin has strong preclinical lifespan data (Yousefzadeh 2018) but its completed human data so far is pharmacokinetic/safety, with outcome trials still running. The more potent preclinical senolytics (navitoclax) are limited by toxicity in humans. For per-molecule tiers, see our longevity drug evidence index.
Are dasatinib and quercetin safe for anti-aging use?
They are not approved or established for anti-aging use, and this page does not recommend them. Dasatinib is a potent FDA-approved chemotherapy drug with a real side-effect profile; the completed human senolytic data used it in a specific disease context under medical supervision, not as a wellness regimen. Quercetin alone is a mild dietary supplement, but the human senolytic signal comes from the combination, not quercetin solo. Whether any senolytic is appropriate for a given person is an individualized medical decision, not a supplement purchase.
Does fisetin extend human lifespan?
That is unproven. Fisetin extended healthspan and lifespan in aged mice (Yousefzadeh 2018) and is one of the most actively studied senolytics, with several human outcome trials underway. But completed human data so far is pharmacokinetic and safety, not lifespan or even a confirmed clinical outcome. Fisetin is widely sold as a longevity supplement ahead of that evidence — honest framing puts it at the C/D boundary for human evidence.
Why are BCL-2 inhibitors like navitoclax not used as senolytics in humans?
Because of their toxicity. Navitoclax (ABT-263) is one of the most potent preclinical senolytics ever tested, but it inhibits BCL-xL, which platelets depend on to survive — so it causes thrombocytopenia (dangerously low platelets) in humans. That toxicity is exactly why a powerful animal-model senolytic does not become a safe longevity therapy. Venetoclax (ABT-199) is BCL-2-selective and gentler on platelets, but its senolytic use for aging is still preclinical/early-stage. Neither is a consumer intervention.
Are senolytics FDA-approved?
No senolytic is FDA-approved for aging or for clearing senescent cells. Several compounds with senolytic activity are FDA-approved for other purposes — dasatinib and venetoclax for certain cancers — but those approvals are not senolytic or longevity evidence. The completed human senolytic data that exists is small and early-stage. This is a frontier, not a pharmacy shelf.
Should I take senolytics for longevity?
That is not a question this page answers with a yes, because the human evidence is not there yet for most people. Cellular senescence is a real hallmark of aging and senolytics are a genuinely promising research direction, so we track them closely. But the honest state today is: one small completed human trial (D+Q), a flavonoid whose human outcome trials are still running (fisetin), and a pipeline of preclinical compounds. The highest-evidence lever against senescent-cell burden today is lifestyle — exercise and healthy body composition are associated with lower burden. Any consideration of an experimental senolytic belongs in a conversation with a physician, not a supplement checkout.
Are senolytics available in Las Vegas or by telehealth?
The research is the same everywhere, but the marketing intensity varies. Las Vegas has a dense market of longevity and med-spa offerings that sell senolytic supplements and protocols well ahead of the completed human evidence — often presenting early-stage compounds as established anti-aging regimens. Whether you visit our southeast Las Vegas clinic at Eastern Avenue and the 215 from Henderson, Summerlin, or Green Valley — or meet Dr. Kamen by secure telehealth anywhere in Nevada — the conversation is the same: an honest read of where each compound actually sits in the evidence, and what an evidence-based plan looks like for your goals.
Related reading: Longevity Drug Evidence-Grade Index · The 12 Hallmarks of Aging · Biological Age Tests Compared · Longevity biomarker ranges
Physician-Led in Las Vegas
Frontier science, honest framing.
A board-certified neurologist will tell you exactly where senolytics sit in the human evidence — what is promising, what is preclinical, and what an evidence-based plan looks like for your goals beyond the hype.
Ready to start your longevity care?
Book your $88 evaluation with Dr. Kamen today, online, by phone, or by text.
Book Your $88 EvaluationPrefer to talk? Call (702) 808-2650 or text us to book.
Physician-led peptide therapy in Las Vegas. Visit our clinic